The Evolving Immunotherapeutic Landscape in Renal Cell Carcinoma

Released On
August 30, 2019

Expires On
August 30, 2020

Media Type

Completion Time
60 minutes

Hematology, Oncology

Renal Cell Cancer

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).


Supported by educational grants from Eisai, EMD Serono and Pfizer.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Pharmacists — 1.0 contact hours of continuing pharmacy education credit.
  • Nurses — 1.0 contact hours.

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

The target audience for this initiative includes medical oncologists, urologic oncologists, nephrologists, advanced practice providers (nurse practitioners, physician assistants, oncology pharmacists), oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with RCC.

Program Overview

This initiative aims to provide guidance to the multidisciplinary cancer care team on the practical issues and barriers associated with incorporating immunotherapies in the treatment of RCC in the community setting. This initiative will review the rationale for combining immunotherapies with an angiogenesis inhibitor, vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI), optimal drug combinations, sequencing of therapies, patient selection criteria and monitoring and managing immune-related adverse events (irAEs)

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review available evidence for approved therapies, including immunotherapy combinations, for patients with clear cell histology
  • Discuss clinical challenges in individualizing and optimizing treatment selection and sequencing
  • Explore strategies for identification and management of immune-related adverse events associated with immunotherapy-inclusive regimens
  • Outline effective approaches to engage patients and their caregivers to actively participate in shared clinical decision making



Robert A. Figlin, MD, FACP

Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology Oncology
Deputy Director, Integrated Oncology Service Line
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center


Jocelyn Mohs, PharmD, BCOP

Pharmacy Supervisor – Infusion Clinic Pharmacy
Sanford Roger Maris Cancer Center


Laura Wood, RN, MSN, OCN

Renal Cancer Research Coordinator
Cleveland Clinic Taussig Cancer Institute

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change

Credit Designation Statement

Physician Continuing Medical Education Credit Designation

AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists Credit Designation

This application-based activity is approved for 1.0 contact hours of continuing pharmacy education credit JA4008106-9999-19-027-H01-P.

Nursing Continuing Education Credit Designation

AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Disclosures of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Robert A. Figlin, MD

  • Contracted research: Peloton, Calithera Biosciences, Inc., Bristol Myers Squibb, Merck, Exelixis and Roche.

Jocelyn Mohs, PharmD, BCOP

  • Nothing to disclose.

Laura Wood, RN, MSN, OCN

  • Advisor/Consultant: Eisai; Speakers bureau: Bristol Myers Squibb, Merck and Pfizer.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Latha Shivakumar, PhD , has nothing to disclose.
Mary Stanley, has nothing to disclose.
Leigh M. Boehmer, PharmD, BCOP, has nothing to disclose.
Marilyn Haas, PhD, RN, CNS, ANP-BC, has nothing to disclose.
Dee Morgillo, MEd.,CHCP, has nothing to disclose.
Linda Gracie King, has nothing to disclose.
Robert Mocharnuk MD: Common Stock: Merck.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the accreditation of this program please contact AXIS at